Health News, Berita Online Indonesia Di Online News Indonesia, www.olnewsindonesia.com
Minister of Health (Menkes) Budi Gunadi Sadikin said that the government prioritized domestically produced COVID-19 vaccines in the national vaccination program. Currently, there are two types of domestically produced vaccines, namely the IndoVac Vaccine and the AWCorna Vaccine.
“Now the focus is on buying domestic vaccines, one of which has Biofarma and possibly later from Airlangga University. We have a small backup of imported vaccines in October,” said the Minister of Health, quoted from the official website of the Ministry of Health, Tuesday (18/10/2022).
In addition, to ensure the availability of vaccines in all regions, the government will relocate vaccine stocks from areas with more vaccine stocks to areas that lack vaccines.
“Now we are relocating the COVID-19 vaccine from the province with the most vaccine stocks, first moving the stock to the province where the rate of injection is fast. In the next 1-2 weeks, the limited stock of this vaccine will gradually be available again,” said Head of the Communication and Public Service Bureau, Ministry of Health, Siti Nadia Tarmizi.
The current stock of COVID-19 vaccines amounts to around 1.2 million doses, with details of 200 thousand vaccine doses allocated at the center and 1 million doses allocated in the regions.
IndoVac vaccine is a vaccine developed by PT Biofarma in collaboration with Baylor College of Medicine, United States of America. This vaccine has an emergency use authorization (EUA) from the Food and Drug Supervisory Agency (BPOM). This vaccine is ready to be used for primary vaccines for people who have not received the COVID-19 vaccine.
Meanwhile, the AWcorna vaccine is a vaccine produced by PT Etana Biotechnologies Indonesia. This vaccine has also received EUA from BPOM and can be an alternative vaccine that can be used in the COVID-19 vaccination program for adults aged 18 years and over.